Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Recent advances in biomaterials for osteosarcoma treatment

Han J., Huo M., Jia C., Zhang B., Zhang F., Meng Q.

Narrative Review on Systemic / IV, published in Regen Biomater (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Regen Biomater (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41822119
PMCID
PMC12975341
DOI
10.1093/rb/rbaf087
Citations
1

Abstract (original English)

Osteosarcoma is a highly aggressive bone malignancy with poor prognosis due to high metastasis and drug resistance. Conventional treatments often result in systemic toxicity and limited efficacy, highlighting the need for more precise and integrative approaches. Biomaterials with excellent biocompatibility and functional tunability have emerged as promising tools to enhance local therapy and support bone regeneration. This review summarizes recent advances in the application of natural, synthetic and composite biomaterials in four key areas: drug delivery, gene therapy, immunotherapy and post-resection bone repair. To provide a systematic perspective, we compiled and classified 64 representative studies published between 2021 and 2025, comparing biomaterial-based delivery strategies ranging from single-material carriers to multifunctional composite platforms. Particular focus is given to stimuli-responsive systems and scaffolds that integrate antitumor activity with regenerative capacity. By outlining emerging strategies and material platforms, this review offers a concise reference for the rational design of biomaterials addressing the dual challenge of tumor eradication and skeletal reconstruction. Interdisciplinary collaboration will be key to advancing these systems toward clinical application.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research